SUMMARY A controlled trial of carbenoxolone sodium positioned-release capsules (Duogastrone) was carried out on a randomized series of 100 unselected male Service personnel with symptoms of active duodenal ulceration and supporting radiological evidence. Fifty-seven patients completed the trial, 29 in the carbenoxolone group and 28 in the control group. The carbenoxolone group was given capsules containing 50 mg carbenoxolone four times a day for 12 weeks while the controls received a capsule identical in every respect except that it did not contain carbenoxolone. All patients were assessed at fortnightly intervals and had clinical and radiological reassessments three and six months after commencing treatment.
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Review at three months and at six months revealed a slight but clinically insignificant trend in favour of the carbenoxolone group.
As a corollary to this controlled trial, those patients (38 in all) who did not have an early remission of symptoms were removed from the trial and placed on capsules known to contain carbenoxolone. Subsequently these patients did not show an advantage for carbenoxolone.
Carbonexolone sodium has been shown in several controlled trials to increase the rate of healing of chronic gastric ulcers in the ambulant patient (Doll, Hill, Hutton, and Underwood, 1962; Doll, Hill, and Hutton, 1965; Horwich and Galloway, 1965; Turpie and Thomson, 1965; Bank, Marks, Palmer, Groll, and Van Eldik, 1967 (Cliff, 1968) ; the response to carbenoxolone sodium capsules was so satisfactory and confirmed by other preliminary studies (Craig, Hunt, Kimerling, and Parke, 1967; Hunt, 1968; Lawrence, Manton, Mendl, and Montgomery, 1968 ) that a double-blind controlled trial against placebo was set up. We now report our findings in 100 patients who have been followed up for six months.
Material and Methods
One hundred unselected male Service personnel with symptoms of an ulcer dyspepsia and radiological evidence of deformity of the duodenum were accepted into the trial. All patients recorded the number of tablets of magnesium trisilicate used during their 12 week course of treatment. The mean alkali consumption for the carbenoxolone group was 48-2 tablets compared with 48.8 tablets in the controls.
One patient went into complete remission during his three months course of coded carbenoxolone but had a perforated duodenal ulcer two months later.
RESULTS IN CASES TRANSFERRED FROM THE CONTROLLED TRIAL TO KNOWN CARBEN-OXOLONE
As indicated in the protocol, those patients who did not have an early remission of symptoms were removed from the controlled trial and given capsules known to contain carbenoxolone; then, unless they were withdrawn on account of persisting symptoms, they received a full 12 week course of this preparation. The transfer to known carbenoxolone usually occurred after six weeks in the controlled trial, the time varying between three weeks and 10 weeks.
In this way 20 patients were transferred from placebo to known carbenoxolone, of whom four were withdrawn with persisting symptoms. After six months the final review showed that five of the remainder had achieved 8-9 points, seven a score of 7 points and four showed little or no improvement. Eighteen cases were transferred from coded carbenoxolone to known carbenoxolone. Six were withdrawn with continuing symptoms and one was discarded as an unreliable witness; of the remaining eleven cases, six attained scores of 8-9 points and the remaining five showed some improvement.
These groups are too small for analysis but they certainly do not show a true trend in favour of carbenoxolone.
SIDE EFFECTS
One patient on carbenoxolone complained that the capsules made him vomit while another experienced depression while taking these capsules; on the other_hand one subject attributed pain to swallowing placebo capsules and another felt that the placebo caused extrasystoles.
Fluid retention, hypertension, potassium loss, and heartburn can occur during the administration of carbenoxolone tablets (Biogastrone), especially in the presence of overt cardiac and renal disease (Turpie and Thomson, 1965) but the positioned-release capsules (Duogastrone) produced no such side effects in a group of 32 patients (Craig et al, 1967) ; in another series of 22 patients mild hypokalaemia and fluid retention was noted on two occasions (Montgomery, A douible-blind trial of carbenoxolone sodium capsules in the treatment ofduodenal ulcer Lawrence, Manton, Mendl, and Rowe, 1968) and one example of hypokalaemia with muscle paresis has been reported in a patient taking carbenoxolone 200 mg daily in the form of Duogastrone for a period of six weeks (Forshaw, 1969) .
If a gain in weight of more than 7 lb (3-2 kg) during the three months' course of treatment should be accepted as evidence of fluid retention, there were eight such patients in this series, seven of whom were taking carbenoxolone and one the placebo; their ages ranged between 18 and 37 years. The only patient to develop minimal pitting oedema during his course of carbenoxolone was aged 37 and he gained 12 lb (5 4 kg in weight; at the same time his blood pressure rose from 130/70 to 160/100 mm of mercury.
In this series no subject showed clinical evidence of hypokalaemia and analysis of the serum potassium and sodium levels showed no difference between those taking carbenoxolone or placebo.
An elevation of the serum transaminase levels has been reported during the metabolic studies of a single patient (Baron, Nabarro, Slater, and Tuffley, 1969) . In this group of 100 patients, either the SGOT or the SGPT was raised above 30 units/ml iTn 10 subjects for a short period during their course of treatment; six had been taking carbenoxolone while four had been receiving placebo.
Discussion
The clinical assessment of the progress of duodenal ulceration must be based on the presence or absence of pain and epigastric tenderness as well as the radiological findings. Although no single aspect can be considered in isolation, the presence of pain is certainly the feature which will undoubtedly lead to further morbidity. Particular attention was therefore paid to the relief of pain in this controlled trial but no difference was noted between those taking carbenoxolone or placebo.
Preliminary trials of carbenoxolone positionedrelease capsules in Servicemen at duty on a normal Service diet (Cliff, 1968) indicated that the course of treatment should last for 12 weeks rather than six weeks and this view was also advanced by Montgomery et al (1968) . In the present controlled trial, treatment was continued for 12 weeks but no clinical advantage for carbenoxolone was revealed.
